Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis

Published:2019-01-15 Issue:1 Volume:17 Page:
ISSN:1741-7015
Container-title:BMC Medicine
language:en
Short-container-title:BMC Med

Author:

Bolton Monica,Hodkinson Alex,Boda Shivani,Mould Alan,Panagioti Maria,Rhodes Sarah,Riste Lisa,van Marwijk Harm

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12916-018-1242-0.pdf

Reference73 articles.

1. Joint Formulary Committee, editor. British National Formulary (BNF) 75 (March 2018). 73rd ed. London: BMJ Publishing Group Ltd and Royal Pharmaceutical Society; 2018. p. 1600.

2. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545–602.

3. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1459–544.

4. Bramness JG, Mann K, Wurst FM. Marketing status and perceived efficacy of drugs for supporting abstinence and reducing alcohol intake in alcohol use disorders: a survey among European Federation of Addiction Societies in Europe. Eur Addict Res. 2016;22:318–21.

5. Thompson A, Ashcroft DM, Owens L, van Staa TP, Pirmohamed M. Drug therapy for alcohol dependence in primary care in the UK: A Clinical Practice Research Datalink study. PLoS One. 2017;12:e0173272.

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety of naltrexone in patients with cirrhosis;JHEP Reports;2024-07

2. Investigation into the restoration of TRPM3 ion channel activity in post-COVID-19 condition: a potential pharmacotherapeutic target;Frontiers in Immunology;2024-05-03

3. Treatment of alcohol use disorder in patients with alcohol-associated liver disease: Innovative approaches and a call to action;Addiction Science & Clinical Practice;2024-03-19

4. Management of alcohol withdrawal syndrome in patients with alcohol-associated liver disease;Hepatology Communications;2024-01-22

5. Closing the Care Gap: Management of Alcohol Use Disorder in Patients with Alcohol-associated Liver Disease;Clinical Therapeutics;2023-12